Literature DB >> 16263606

Current management: Management of rheumatic diseases in the era of biological anti-rheumatic drugs.

Yrjö T Konttinen1, Seppo Seitsalo, Matti Lehto, Seppo Santavirta.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16263606     DOI: 10.1080/17453670510041673

Source DB:  PubMed          Journal:  Acta Orthop        ISSN: 1745-3674            Impact factor:   3.717


× No keyword cloud information.
  6 in total

1.  Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept.

Authors:  V Bagalas; I Kioumis; P Argyropoulou; D Patakas
Journal:  Clin Rheumatol       Date:  2006-07-25       Impact factor: 2.980

2.  An endogenous TNF-alpha antagonist induced by splice-switching oligonucleotides reduces inflammation in hepatitis and arthritis mouse models.

Authors:  Maria A Graziewicz; Teresa K Tarrant; Brian Buckley; Jennifer Roberts; LeShara Fulton; Henrik Hansen; Henrik Ørum; Ryszard Kole; Peter Sazani
Journal:  Mol Ther       Date:  2008-05-06       Impact factor: 11.454

3.  New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval.

Authors:  Vittorio Bertele'; Alessandro Assisi; Valeria Di Muzio; Danila Renzo; Silvio Garattini
Journal:  Eur J Clin Pharmacol       Date:  2007-07-24       Impact factor: 2.953

Review 4.  Prevention of deep infection in joint replacement surgery.

Authors:  Esa Jämsen; Ove Furnes; Lars B Engesaeter; Yrjö T Konttinen; Anders Odgaard; Anna Stefánsdóttir; Lars Lidgren
Journal:  Acta Orthop       Date:  2010-12       Impact factor: 3.717

5.  Alpha-methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy.

Authors:  Jungyeon Hwang; Kathleen Rodgers; James C Oliver; Thomas Schluep
Journal:  Int J Nanomedicine       Date:  2008

6.  Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate.

Authors:  A Kavanaugh; L Klareskog; D van der Heijde; J Li; B Freundlich; M Hooper
Journal:  Ann Rheum Dis       Date:  2008-06-05       Impact factor: 19.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.